A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBA
What they do
Estuary Biotherapeutics announced its launch on October 16, 2026 with $103M in total committed financing, comprising a $93M Series A and $10M seed financing. The company develops kidney-directed gene therapies. Wayne Sackett is CEO and co-founder; the financing does not establish clinical efficacy or approval.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Kidney gene therapy
- Product type
- Stage
- Series A
- Headquarters
- Not disclosed
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $103M raised
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
He Lived 271 Days on a Pig Kidney. Then His Body Told Doctors It Was Time to Switch.
Dr. Dereck Mush, MD, MBA
CDMOs race to add capacity as cell and gene therapy demand outpaces supply
Dr. Dereck Mush, MD, MBA
The AAV9 CNS Blueprint: Inside Ultragenyx's Landmark Fayuvi Approval
Dr. Dereck Mush, MD, MBA